SEC Form 4 · accession 0001104659-26-088665
Yarrow Bioscience, Inc. · YARW
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Period of report
Jul 29, 2026
Accepted (ET)
Jul 30, 2026 · 4:05 pm EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0001566044
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF2 | Jul 29, 2026 | J | 133,290 | $0.00 | D | 266,307 | I | See footnote |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Pre-Funded Warrants (Right to Buy)F2,F3 | $0.0001 | Jul 29, 2026 | J | 133,290 | A | — | — | Common Stock | 133,290 | 8,949,719 | I |
Explanation of responses
- F1Pursuant to the terms of that certain Exchange Agreement, dated as of July 29, 2026, RTW Entity (as defined below) exchanged 133,290 shares of the Issuer's common stock for pre-funded warrants to purchase an equivalent number of shares of the Issuer's common stock.
- F2Held by a certain affiliated entity ("RTW Entity") managed by RTW Fund Group GP, LLC ("RTW Fund Group"). Roderick Wong, M.D. serves as the Managing Member of RTW Fund Group. The Reporting Persons disclaim beneficial ownership of the reported securities for purposes of Section 16 under the Securities Exchange Act of 1934, as amended, except to the extent of their pecuniary interest therein.
- F3The pre-funded warrants to purchase shares of the Issuer's common stock (the "Pre-Funded Warrants") have no expiration date and are exercisable at any time after the date of issuance. A holder of Pre-Funded Warrants may not exercise the Pre-Funded Warrant if the holder, together with its affiliates, would beneficially own more than 9.99% of the number of shares of common stock outstanding immediately after giving effect to such exercise.